Provided by Tiger Trade Technology Pte. Ltd.

Vaxcyte, Inc.

53.16
-1.5500-2.83%
Post-market: 53.00-0.1600-0.30%18:19 EDT
Volume:995.59K
Turnover:53.36M
Market Cap:7.66B
PE:-9.44
High:55.52
Open:55.21
Low:52.89
Close:54.71
52wk High:71.22
52wk Low:27.66
Shares:144.00M
Float Shares:116.97M
Volume Ratio:0.57
T/O Rate:0.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.6300
EPS(LYR):-5.6333
ROE:-25.59%
ROA:-17.72%
PB:2.85
PE(LYR):-9.44

Loading ...

Vaxcyte Inc. to report financial results and provide business update

Reuters
·
Feb 11

Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit

GlobeNewswire
·
Feb 06

Vaxcyte Closes Public Offering of Shares

MT Newswires Live
·
Feb 03

Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

GlobeNewswire
·
Feb 03

Vaxcyte Price Target Maintained With a $116.00/Share by Guggenheim

Dow Jones
·
Feb 02

Vaxcyte (PCVX) Valuation Check After $550 Million Follow On Equity Offering

Simply Wall St.
·
Feb 02

BUZZ-U.S. STOCKS ON THE MOVE-ResMed, Stryker, ALX Oncology

Reuters
·
Jan 30

BUZZ-Vaxcyte edges higher after upsized $550 mln equity raise

Reuters
·
Jan 30

Vaxcyte Inc - Selling 11,000,000 Shares at $50 per Share

THOMSON REUTERS
·
Jan 30

Vaxcyte Announces Pricing of $550 Million Public Offering

THOMSON REUTERS
·
Jan 30

Vaxcyte secondary being re-offered at $50 per share

TIPRANKS
·
Jan 30

Vaxcyte offering marketed at $50 per share, Bloomberg says

TIPRANKS
·
Jan 30

Vaxcyte Launches $500 Million Public Offering

MT Newswires Live
·
Jan 30

Vaxcyte Inc - Commences $500 Mln Public Offering

THOMSON REUTERS
·
Jan 30

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire
·
Jan 30

Why Vaxcyte (PCVX) Is Up 13.2% After Advancing Adult Phase 3 And Infant VAX-31 Trials

Simply Wall St.
·
Jan 26

Analysts Are Bullish on These Healthcare Stocks: Vaxcyte (PCVX), Guardant Health (GH)

TIPRANKS
·
Jan 24

Why Your Pneumonia Shot Is About To Get A Massive Upgrade

Benzinga_recent_news
·
Jan 23

Vaxcyte provides update on development of VAX-31 pneumococcal vaccine

TIPRANKS
·
Jan 23

Vaxcyte: Vax-31 Adult Phase 3 Noninferiority Trial (Opus-1) Continues to Enroll Subjects, With Topline Data Expected in Fourth Quarter of 2026

THOMSON REUTERS
·
Jan 23